FASEB J. Mp Biomedicals
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
18/13/1571
04-1994fjev1    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qing, H.
Right arrow Articles by Song, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qing, H.
Right arrow Articles by Song, W.
The FASEB Journal Express Article doi:10.1096/fj.04-1994fje
Published online August 2, 2004

Degradation of BACE by the ubiquitin-proteasome pathway

Hong Qing, Weihui Zhou, Michelle A. Christensen, Xiulian Sun, Yigang Tong, and Weihong Song

E-mail contact: weihong{at}interchange.ubc.ca

The amyloid β protein (Aβ) is derived from β-amyloid precursor protein (APP). Cleavage of APP by β-secretase generates a C-terminal fragment (APPCTFβ or C99), which is subsequently cleaved by γ-secretase to produce Aβ. BACE (or BACE1), the major β-secretase involved in cleaving APP, has been identified as a Type 1 membrane-associated aspartyl protease. In this study, we found that treatment with proteasome inhibitors resulted in an increase in APP C99 levels, suggesting that APP processing at the β-secretase site may be affected by the ubiquitin-proteasome pathway. To investigate whether the degradation of BACE is mediated by the proteasome pathway, cells stably transfected with BACE were treated with lactacystin. We found that BACE protein degradation was inhibited by lactacystin in a time- and dose-dependent manner. Non-proteasome protease inhibitors had no effect on BACE degradation. BACE protein is ubiquitinated. Furthermore, lactacystin increased APP C99 production and Aβ generation. Our data demonstrate that the degradation of BACE proteins and APP processing are regulated by the ubiquitin-proteasome pathway.

Key words: Alzheimer's Disease • APP • Aβ




This article has been cited by other articles:


Home page
FASEB J.Home page
H. Liu, P. Wang, W. Song, and X. Sun
Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways
FASEB J, October 1, 2009; 23(10): 3383 - 3392.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
H. Qing, G. He, P. T. T. Ly, C. J. Fox, M. Staufenbiel, F. Cai, Z. Zhang, S. Wei, X. Sun, C.-H. Chen, et al.
Valproic acid inhibits A{beta} production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models
J. Exp. Med., November 24, 2008; 205(12): 2781 - 2789.
[Abstract] [Full Text] [PDF]


Home page
RNAHome page
K. Sipa, E. Sochacka, J. Kazmierczak-Baranska, M. Maszewska, M. Janicka, G. Nowak, and B. Nawrot
Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA
RNA, August 1, 2007; 13(8): 1301 - 1316.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. Zhao, Y. Fu, M. Yasvoina, P. Shao, B. Hitt, T. O'Connor, S. Logan, E. Maus, M. Citron, R. Berry, et al.
{beta}-Site Amyloid Precursor Protein Cleaving Enzyme 1 Levels Become Elevated in Neurons around Amyloid Plaques: Implications for Alzheimer's Disease Pathogenesis
J. Neurosci., April 4, 2007; 27(14): 3639 - 3649.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
X. Sun, Y. Tong, H. Qing, C.-H. Chen, and W. Song
Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome
FASEB J, July 1, 2006; 20(9): 1361 - 1368.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
X. Sun, G. He, and W. Song
BACE2, as a novel APP {theta}-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome
FASEB J, July 1, 2006; 20(9): 1369 - 1376.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
W. Zhou and W. Song
Leaky Scanning and Reinitiation Regulate BACE1 Gene Expression
Mol. Cell. Biol., May 1, 2006; 26(9): 3353 - 3364.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
Y. Li, W. Zhou, Y. Tong, G. He, and W. Song
Control of APP processing and A{beta} generation level by BACE1 enzymatic activity and transcription
FASEB J, February 1, 2006; 20(2): 285 - 292.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. H. Koh, C. A. F. von Arnim, B. T. Hyman, R. E. Tanzi, and G. Tesco
BACE Is Degraded via the Lysosomal Pathway
J. Biol. Chem., September 16, 2005; 280(37): 32499 - 32504.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
X. Sun, Y. Wang, H. Qing, M. A. Christensen, Y. Liu, W. Zhou, Y. Tong, C. Xiao, Y. Huang, S. Zhang, et al.
Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes
FASEB J, May 1, 2005; 19(7): 739 - 749.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2004 by The Federation of American Societies for Experimental Biology.